financetom
Business
financetom
/
Business
/
Viking Likely to Deliver Q2 Beat, Booking Curve May Improve Versus Q1, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Viking Likely to Deliver Q2 Beat, Booking Curve May Improve Versus Q1, Morgan Stanley Says
Aug 20, 2024 8:08 AM

10:56 AM EDT, 08/20/2024 (MT Newswires) -- Viking Holdings ( VIK ) Q2 results will likely come in ahead of consensus estimates, while the company's updated forward booking curve is expected to be consistent with or slightly better than in Q1, Morgan Stanley said in a note Tuesday.

The company is scheduled to report its Q2 results on Thursday.

Viking will likely post Q2 gross revenues of $1.68 billion, above the consensus estimate of $1.6 billion, as Q2 "demand commentary from earnings for other operators remains healthy and our channel checks have stayed strong," according to the note.

Viking's Q2 net revenue is seen at $1.09 billion, also beating market expectations for $1.04 billion, the investment firm said, adding that adjusted EBITDA will likely be $470 million, above the consensus estimate of $456 million amid decreasing fuel prices and ship-operating expenses.

"While management does not provide specific guidance (and we don't expect that to change), we expect the company to once again disclose its booking curve where we anticipate a sustained strength in 2025," the note added.

"We see a positive setup for [Viking] heading into the print, which we believe should provide further relief to the shares and broader cruise sector," Morgan Stanley said.

The investment firm raised Viking's price target to $35 from $33, with an equal-weight rating.

Price: 35.90, Change: +0.40, Percent Change: +1.13

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Christopher Gibson, Director, Chief Executive Officer, on June 05, 2024, sold 100,000 shares in Recursion Pharmaceuticals ( RXRX ) for $871,000. Following the Form 4 filing with the SEC, Gibson has control over a total of 708,738 shares of the company, with 708,738 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000077/xslF345X03/wk-form4_1717790504.xml Price: 8.60, Change: +0.09,...
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Percy H. Carter, Chief Scientific Officer, on June 05, 2024, sold 4,000 shares in Blueprint Medicines ( BPMC ) for $420,520. Following the Form 4 filing with the SEC, Carter has control over a total of 41,895 shares of the company, with 41,895 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1597264/000141588924015943/xslF345X03/form4-06072024_040602.xml ...
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Jun 7, 2024
04:06 PM EDT, 06/07/2024 (MT Newswires) -- Robert I Blum, Director, President & CEO, on June 04, 2024, sold 22,500 shares in Cytokinetics ( CYTK ) for $1,099,125. Following the Form 4 filing with the SEC, Blum has control over a total of 443,311 shares of the company, with 439,145 shares held directly and 4,166 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1061983/000112760224018143/xslF345X03/form4.xml...
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Ronald M Shaich, Director, on June 05, 2024, sold 2,550,290 shares in Cava Group ( CAVA ) for $222,512,803. Following the Form 4 filing with the SEC, Shaich has control over a total of 7,149,899 shares of the company, with 5,000 shares held directly and 7,144,899 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1639438/000162828024027251/xslF345X03/wk-form4_1717790405.xml Price: 85.00,...
Copyright 2023-2025 - www.financetom.com All Rights Reserved